Apellis Pharmaceuticals, Inc. (APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat.

With competition encroaching, Alexion executives are pushing plans to more than double the company’s product portfolio in the next three years, including at least one “high risk, high reward” drug candidate.

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1.425 million additional shares of its common stock at the public offering price, less the underwriting discount and commissions.

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”) for an aggregate purchase price of $328.9 million. The private placement is expected to close on May 12, 2020, subject to satisfaction of customary closing conditions. The notes issuance is a reopening of, and will form a single series with, and have the same terms as, Apellis’ $220 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “existing notes”) issued on September 16, 2019, but will have a different issue date, issue price, CUSIP number and different restrictions on transfer.

Results from positive Phase 3 PEGASUS study in PNH selected for oral presentation at the 2020 European Hematology Association CongressPEGASUS showed superiority of pegcetacoplan.

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020. Based on feedback from the U.S. Food and Drug Administration (FDA) during a pre-NDA meeting to discuss the registration strategy for pegcetacoplan, Apellis plans to submit the NDA with results from the Phase 3 PEGASUS trial comparing pegcetacoplan to eculizumab in patients with PNH.

Positive Top-line Results Announced from Head-to-Head Phase 3 PEGASUS Trial of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The stock market rally hit new highs despite an Iran missile attack. Tesla, Costco and Beyond Meat rallied. A Boeing 737 crash was just one of several big headlines for the aerospace giant.

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

WALTHAM Mass., Jan. 13, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of.

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of equity awards to three new employees with grant dates of May 1, 2020 and May 4, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company. The employees received, in the aggregate, options to purchase 112,526 shares of Apellis common stock. 8,250 of these options have an exercise price of $32.02 per share, which is equal to the closing price of Apellis common stock on May 1, 2020, the grant date of these options.

The former Louisville-area company sold about 1.4 million more shares that were part of an option held by financial firms involved with the public stock offering.

We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 45.7% last year and beat the S&P 500 ETFs by […]

Full Enrollment of Two Phase 3 Trials in Geographic Atrophy Expected in the Second Quarter of 2020Meetings with US and EU Regulators to Discuss Submissions in Paroxysmal.

Some of Louisville's most prominent and influential health care executives are members of this organization. It's moving forward with two strategic initiatives.

Apellis Pharmaceuticals (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced early data from the Phase 1b APL2-103 study of pegcetacoplan (APL-2) in patients with advanced geographic atrophy (GA) and low vision. The study, which enrolled 12 patients, was initiated to assess the safety of the Phase 3 formulation of pegcetacoplan (15mg/0.1mL). The analysis of APL2-103 has shown that the Phase 3 formulation was well tolerated over 12 months of treatment.

WALTHAM, Mass., Feb. 26, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the.

Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today appointed Paul Fonteyne to its Board of Directors. Mr. Fonteyne’s appointment expands the Board to six directors, five of whom are independent. Mr. Fonteyne brings more than three decades of experience in the biopharmaceutical industry, including leadership roles in the United States and globally with Boehringer-Ingelheim, one of the world's leading pharmaceutical companies.

Apellis Pharmaceuticals Inc. is hoping to garner hundreds of millions of dollars in its latest public stock offering. The late-stage biopharmaceutical company disclosed late Wednesday that it will issue 9.5 million shares of common stock at $37 per share for potential gross proceeds of $351.5 million before certain deductions related to the public offerings. Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group LLC are joint bookrunning managers and underwriters of the offering.